The targeted engineering of artificial proteins with unique properties – that is possible with the assistance of a novel method developed by a research team of Heidelberg University. It centers around a new AI model. This allows for forecasting how two proteins have to be fitted together at the molecular level from individual parts – subunits – in order to engineer a functional, adjustable new protein.

Why do cancers develop differently in different people—even when they are exposed to the same risk factors? An international research group, including the German Cancer Research Center (DKFZ), has now demonstrated in mice that an organism’s genetic makeup significantly influences the course of cancer development.

Tübingen achieves remarkable success and has good chance of maintaining its University of Excellence title – Top research in three areas to be sustained from other sources of support.

EMBL scientists pave the way for reducing the harmful side effects antibiotics have on gut bacteria. Antibiotics help us to treat bacterial infections and save millions of lives each year. But they can also harm the helpful microbes residing in our gut, weakening one of our body’s first lines of defence against pathogens and compromising the multiple beneficial effects our microbiota has for our health.

A new method allows stem cells and cancer stem cells to be studied at the single cell level and the resulting cell clones to be traced directly. Studying thousands of individual cells in parallel, the researchers combined the analysis of the genomic cancer mutations with the associated expression profiles.

Heidelberg University is to acquire a research building to develop innovative engineering science strategies and technologies on the basis of life-inspired molecular systems. The German Science and Humanities Council has now expressed its backing for the idea with an outstanding rating. This recommendation is the crucial precondition for a new building on the university campus Im Neuenheimer Feld.

Researchers at the Faculty of Medicine at the University of Freiburg have gained significant new insights into metabolic processes in the kidney. The scientists from the Institute of Genetic Epidemiology at the Medical Center - University of Freiburg measured tiny molecules, so-called metabolites, which occur in blood and urine and reflect our metabolism, in samples from more than 5,000 study participants.

Stem cell research - 14/03/2024

Using organoids to gain a better clinical understanding of pancreatic cancer

Prof. Dr. Alexander Kleger carries out translational research at Ulm University Hospital to gain a better understanding of pancreatic ductal adenocarcinoma (PDAC) and develop individualised treatments. He and his team are using organoid models and stem cell-based systems and have succeeded in simultaneously cultivating all three main cell types of the pancreas from pluripotent stem cells.

CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced a significant strategic restructuring to focus its resources on high-value mRNA projects in oncology and other select areas of substantial unmet medical need.

Synthetic immunology is the topic of an article in the “Perspectives” section of the journal “Nature Nanotechnology”. Herein, Heidelberg researchers describe a so-called bottom-up approach that uses the toolbox of nanotechnology and synthetic biology to construct systems from molecular building blocks and specifically equip them with immune functions.

The Bayer Foundation's Early Excellence in Science Award 2024 in the category of Data Science goes to Ivana Winkler of the German Cancer Research Center (DKFZ). Winkler's work uncovered the unexpected effect of female reproductive capacity: the constantly recurring remodeling of the organs of the female reproductive tract during the sexual cycle leads to fibrosis and chronic inflammation over the years.

A recent study by the Hector Institute for Translational Brain Research at the CIMH provides the first cellular insights into how psilocin promotes the growth and networking of human nerve cells.

The skeletal muscles of men and women process glucose and fats in different ways. A study provides the first comprehensive molecular analysis of these differences. The results possibly give an explanation why metabolic diseases such as diabetes manifest differently in women and men – and why they respond differently to physical activity.

About five percent of lung adenocarcinomas, one of the most common forms of lung cancer, are driven by a faulty fusion of two genes, EML4 and ALK. This fusion results in different variants, and until now, clinicians have treated all patients with these fusions the same way. However, new research led by scientists from the German Cancer Research Center (DKFZ) and Stanford University shows that not all fusion variants behave alike.

Tumors are not a comfortable place to live: oxygen deficiency, nutrient scarcity, and the accumulation of sometimes harmful metabolic products constantly stress cancer cells. A research team from the DKFZ and the IMP in Vienna has now discovered that the acidic pH value in tumor tissue is a decisive factor in how pancreatic cancer cells adapt their energy metabolism in order to survive under these adverse conditions.

Physician and cancer researcher Mirco Julian Friedrich from the German Cancer Research Center (DKFZ), the stem cell research institute HI-STEM*, and Heidelberg University Hospital (UKHD) has received two awards for two independent research projects: his novel approach to preventing liver metastases and his research on T cells, which he modifies to better protect them from attacks by natural killer cells.

How can artificial intelligence support medical imaging diagnostics in the future and significantly improve patient care? Researchers led by Lena Maier-Hein (German Cancer Research Center, DKFZ, and NCT Heidelberg) have developed an innovative concept to address this question. The Carl Zeiss-Stiftung is funding the MEDAL* project with a total of three million euros.

For the first time, researchers have succeeded in mapping the organization of immune cells in human lymph nodes. The study was led by scientists from Heinrich Heine University Düsseldorf, Düsseldorf University Hospital, the DKFZ, the European Molecular Biology Laboratory (EMBL), and the Max Delbrück Center (MDC) in Berlin. They were able to demonstrate why the architecture of healthy lymph nodes is altered in malignant lymphomas.

Chronic pain is among the most common and burdensome health conditions worldwide. But which processes in the nervous system cause pain to be “learned” and thus persist long term? And how can insights into the mechanisms underlying chronic pain be translated into new therapeutic approaches? These questions have been at the core of Rohini Kuner’s research for many years.

The European Research Council (ERC) supports visionary projects in basic research through its “Advanced Grants.” This year, the Council awarded a grant to cancer researcher and physician Dieter Saur from the DKTK Munich* site, and Aurelio Teleman, a metabolism expert at the German Cancer Research Center (DKFZ).

Article - 14/01/2021

Newly discovered RNA as growth driver in liver cancer

Non-coding RNA (ncRNAs) molecules that do not encode proteins have many different functions, and some are associated with certain diseases. Prof. Dr. Sven Diederichs from the German Consortium for Translational Cancer Research and the German Cancer Research Center in Heidelberg has been conducting research into these molecules at the Freiburg University Medical Centre and discovered a ncRNA that regulates cell proliferation in cancer cells.

Gene regulation as a starting point for cancer therapies - 02/12/2021

New investigation method for deciphering complex epigenetic networks

The development and maintenance of uncontrolled cell division in tumours is often due to the unbalanced, complex interplay of regulatory epigenetic networks. Researchers at the Institute of Biochemistry and Technical Biochemistry in Stuttgart have developed a new screening system to identify essential components that can serve as targets for anticancer drugs.

Today, genome editing is almost as easy as programming software. However, the generation of viral vectors as initial material is still associated with many expensive and error-prone handling procedures. Viruses are generated via complex biological processes that have to be optimised virus-specifically in order to produce high-quality therapeutics. A new method is needed that simplifies and optimises these processes.

Antibodies can improve the rehabilitation of people with acute spinal cord injury. Researchers at 13 clinics in Germany, Switzerland, the Czech Republic and Spain have investigated this with promising results. For the first time, it was possible to identify patient groups that displayed a clinically relevant treatment effect. A follow-up study will start in December 2024.

Prof. Dr. Halbritter has served as the new Medical Director of the Department of Nephrology at the Medical Center – University of Freiburg since April 2026. With his expertise, he is enhancing care for patients with kidney disease: The goal is to prevent kidney failure through early diagnosis and the implementation of strategies to slow disease progression. For cases where kidney failure has already occurred, the focus is on organ replacement.

The reservoir of blood stem cells shrinks with age. It becomes increasingly dominated by stem cells that produce immune cells associated with chronic inflammation. Almost all of the 60-year-olds studied show this change. The new discovery could help explain the chronic inflammation that occurs with age and makes us more susceptible to disease. It could also help identify early warning signs of unhealthy aging processes.

The working group around Dr. Philipp Rathert at the Institute for Biochemistry and Technical Biochemistry investigates the regulation of epigenetic networks of certain cancers and ways of treating them. The working group published its new findings in April.

New drugs are intended to help stop viral zoonoses – infections that jump from animals to humans. To study suitable inhibitors, Prof. Dr Christian Klein from the Institute of Pharmacy and Molecular Biotechnology (IPMB) of Heidelberg University is receiving funding in the amount of 450,000 euros from the Volkswagen Foundation.

Researchers use epigenetic factors to investigate the role of stress in the development of tumor diseases. Experts believe that stress plays a major role in the development of tumors. One occupational group, for example, that experiences extreme stress over a short period of time is astronauts.

The RNA Printer® is CureVac’s integrated and automated manufacturing solution for RNA vaccines and therapeutics. CureVac RNA Printer GmbH to provide dedicated infrastructure to accelerate development and broaden application range of The RNA Printer®. Dr. Markus Bergmann appointed as General Manager for CureVac RNA Printer GmbH.

A phase I clinical trial is now starting at Tuebingen University Hospital in the Clinical Collaboration Unit (CCU) Translational Immunology, in collaboration with the Department of Internal Medicine I, which is investigating the therapeutic cancer peptide vaccine Fusion-VAC-XS15 in combination with immune checkpoint blockade by atezolizumab (Tecentriq®).

Mutations of the tumor suppressor p53 not only have a growth-promoting effect on the cancer cells themselves, but also influence the cells in the tumor's microenvironment. Scientists at the Weizmann Institute in Israel and at the German Cancer Research Center (DKFZ) have now shown that p53-mutated mouse breast cancer cells reprogram fat cells.

PURA syndrome is a rare developmental disorder of the brain for which there is currently no cure. The patient association PURA Syndrome Germany was founded last year. Since then, the affected families have been collecting donations with great dedication – and have decided to donate the majority of this money to research into the syndrome at Ulm University.

Medulloblastomas, childhood brain tumors in children, are thought to develop between the first trimester of pregnancy and the end of the first year of life. Researchers have now published their findings in the journal Nature. They analyzed the genetic changes of each individual cancer cell in tumor samples in order to reconstruct which genetic changes occur first during tumor development and when.

Dr Dr Varun Venkataramani and Dr Moritz Mall have been awarded this year’s Hella Bühler Prize for their outstanding research on the interaction between nerve and tumor cells and on tumor plasticity. The award granted by Heidelberg University goes to young researchers from the Heidelberg research location who have already drawn attention to themselves through the outstanding scientific quality of their cancer research.

The 2020 Nobel Prize in Chemistry was awarded for the development of CRISPR/Cas9, a method also known as “gene scissors”, which enables researchers to better understand how human cells function and stay healthy. Researchers at the University of Stuttgart have further developed CRISPR for this purpose. They present their CRISPRgenee method in Cell Reports Methods.

The Federal Ministry of Research, Technology and Space (BMFTR) is supporting the “Sleep-Neuro-Path” research network with around 1.6 million euros. Coordinated by the Central Institute of Mental Health (CIMH) in Mannheim, a team of scientists is investigating the role of sleep-related biomarkers in the development of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

Neurodegenerative diseases - 12/12/2022

Blood-based biomarkers allow the early prediction of Alzheimer's risks

Most dementia diseases develop insidiously and are only detected at an advanced stage. Researchers at the University of Heidelberg and the German Cancer Research Center (DKFZ) have now identified the glial fibre acidic protein (GFAP) in the blood as a promising biomarker that can be used to determine an increased risk of developing Alzheimer's disease up to 17 years before diagnosis.

Four doctoral candidates from Heidelberg University have the opportunity to exchange ideas with outstanding scientists. They are set to take part in the 75th Lindau Nobel Laureate Meeting, which is being held in Lindau from 28 June to 3 July 2026. Jana Braunger, Tim Schubert, Laura Rueda Gensini and Nathan Trausch are among around 600 young researchers who have been selected for their outstanding academic achievements.

Quantum Technology Ulm - 08/04/2021

Diamonds for life sciences innovations

The world's first commercial quantum computer,’IBM Q System One’, is now in operation in Ehningen near Stuttgart. This is a major leap forward in quantum technology in Germany. It marks the point at which conventional computers reach their limits. The University of Ulm is involved in three of six collaborative projects being funded by the Baden-Württemberg Ministry of Economic Affairs, Labour and Housing Construction.

Scientists at the University of Stuttgart have succeeded in controlling the structure and function of biological membranes with the help of "DNA origami". The system they developed may facilitate the transportation of large therapeutic loads into cells. This opens up a new way for the targeted administration of medication and other therapeutic interventions.

Many people are infected with the Epstein-Barr virus (EBV), and most are unaware of it. However, EBV can sometimes cause cancer, and this pathogen also appears to play an important role in multiple sclerosis and other autoimmune diseases. Researchers have discovered that EBV increases the ability of infected immune cells to migrate. In this way, the pathogen promotes its spread in the body – a discovery that may have therapeutic implications.

Researchers from the Cluster of Excellence CIBSS have demonstrated that an actin scaffold stabilizes the cell nucleus upon mechanical stress. This protective mechanism helps cancer cells to avoid dying during their migration in the body. In the long term, targeted interventions in this mechanism could help to prevent metastases.

Even before a tumour in the pancreas becomes discernible, an activated cancer gene actively remodels its future environment and creates an inflammatory and immune-defensive microenvironment in which the carcinoma can grow. The scientists' study opens up new possibilities for developing personalised intervention strategies - before a difficult-to-treat tumour even develops.

The introduction of mammography screening programs in Europe has significantly changed breast cancer diagnoses, accompanied by a decline in breast cancer mortality rates. This is shown by the most comprehensive analyses of population-based data on breast cancer in 21 European countries to date, led by the DKFZ. The most striking finding: after the introduction of screening, significantly more early-stage, less advanced tumors were detected.

How does sugar affect relaxation exercises? A new study carried out by researchers from the University of Konstanz provides revealing insights into the connection between blood glucose and the autonomic nervous system: The intake of sugar counteracts relaxation.

In rare cases, cancer treatments can cause serious long-term effects. These include so-called secondary leukemias. This form of blood cancer can develop when chemotherapy or radiotherapy damages the genetic material of healthy cells. A research team led by a scientist from Ulm has now discovered a molecular protective mechanism against such genomic damage: a peptide.

On December 13, 2022, the European Commission granted approval to a drug against metastatic prostate cancer whose active ingredient was developed under the leadership of the German Cancer Research Center (DKFZ) in collaboration with Heidelberg University Hospital and Heidelberg University. The drug can significantly improve the survival chances of patients.

Scientists from the German Cancer Research Center (DKFZ) and Medical Faculty Mannheim of the Heidelberg University investigated in mice how spreading tumor cells behave at the site of metastasis: Some tumor cells immediately start to form metastases. Others leave the blood vessel and may then enter a long period of dormancy. What determines which path the cancer cells take is their epigenetic status.

A research team from the Heidelberg Medical Faculty, the German Cancer Research Center, the Berlin Institute of Health at Charité (BIH) and the Max Delbrück Center has discovered new details about the spread of the incurable bone marrow cancer multiple myeloma in the body: When the cancer cells break out of the bone and multiply outside the bone marrow, a wide variety of tumor cells arise, accompanied by a significantly altered immune response.